Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

105.24USD
12:58pm EST
Change (% chg)

$0.74 (+0.71%)
Prev Close
$104.50
Open
$104.96
Day's High
$106.11
Day's Low
$104.95
Volume
792,025
Avg. Vol
2,028,860
52-wk High
$147.13
52-wk Low
$94.56

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $82,274.62
Shares Outstanding(Mil.): 787.32
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.69 15.46
EPS (TTM): -- -- --
ROI: -- 15.18 11.85
ROE: -- 16.59 15.83

BRIEF-Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA

* Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma

Nov 16 2017

U.S. opposes 'windfall' award to Celgene whistleblower

The U.S. Justice Department is opposing a former Celgene Corp sales manager's request for a nearly $77.8 million share of a recent $280 million settlement with the drugmaker, saying the sum would amount to an "inappropriate windfall."

Nov 15 2017

Celgene whistleblower seeks dismissal of law firm's lawsuit

A former Celgene Corp sales manager has urged a federal judge to dismiss a lawsuit by law firm Grant & Eisenhofer, which is seeking a cut of a $280 million settlement of a whistleblower lawsuit in which it previously represented her.

Nov 14 2017

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

Nov 14 2017

BRIEF-Celgene prices $3 billion of senior unsecured notes

* Celgene Corp - ‍announced pricing of three series of senior unsecured notes for aggregate principal amount of $3,000 million​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 01 2017

BRIEF-Celgene announces offering of senior unsecured notes

* Celgene-To use proceeds for repayment of $1 billion outstanding 2.125% senior notes & $400 million outstanding 2.300% senior notes, each maturing Aug 2018​ Source text for Eikon: Further company coverage:

Oct 31 2017

BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid

* Lannett and Celgene enter into settlement and license agreement related to Thalomid

Oct 30 2017

BRIEF-Celgene Corp updates on court order at request of Canadian Competition Bureau - SEC filing

* Celgene Corp says ‍​in Aug, co received an order issued by the Federal Court in Ottawa, Ontario, Canada at request of Canadian Competition Bureau

Oct 26 2017

Celgene cuts 2020 outlook, Otezla sales disappoint; shares plunge

Celgene Corp on Thursday reported third-quarter sales of its key psoriasis drug Otezla that badly missed expectations and significantly scaled down its 2020 targets for product sales and earnings, sending its shares tumbling 18 percent.

Oct 26 2017

UPDATE 5-Celgene cuts 2020 outlook, Otezla sales disappoint; shares plunge

Oct 26 Celgene Corp on Thursday reported third-quarter sales of its key psoriasis drug Otezla that badly missed expectations and significantly scaled down its 2020 targets for product sales and earnings, sending its shares tumbling 18 percent.

Oct 26 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,155 -24.00
Eisai Co., Ltd (4523.T) ¥6,295 -49.00
Johnson & Johnson (JNJ.N) $136.91 -1.43
Novartis AG (NOVN.S) CHF83.30 -0.25
Pfizer Inc. (PFE.N) $35.44 -0.09
Roche Holding Ltd. (ROG.S) CHF246.80 +2.80
Roche Holding Ltd. (RO.S) CHF248.40 +2.80
Merck & Co., Inc. (MRK.N) $54.34 +0.07
Sanofi SA (SASY.PA) €76.71 +0.27
AstraZeneca plc (AZN.L) 5,007.00 -29.00

Earnings vs. Estimates